OTCMKTS:ZLDPF Zealand Pharma A/S (ZLDPF) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free ZLDPF Stock Alerts $86.17 -1.06 (-1.22%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$86.17▼$87.2650-Day Range$67.93▼$111.1952-Week Range$32.42▼$111.44Volume996 shsAverage Volume2,665 shsMarket Capitalization$4.44 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest Get Zealand Pharma A/S alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Zealand Pharma A/S Stock (OTCMKTS:ZLDPF)Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.Read More ZLDPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZLDPF Stock News HeadlinesApril 17, 2024 | msn.comAuckland to Northland expressway will boost GDP by $1.2b a year, report showsApril 17, 2024 | bloomberg.comA Double-Dip Recession in the Land of the Long White CloudApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 11, 2024 | msn.comAuckland's newest social supermarket officially opensApril 3, 2024 | markets.businessinsider.comUnveiling New Zealand's Most Deadly Urban Pest: A Comprehensive ExaminationMarch 31, 2024 | finance.yahoo.comTotal number of shares and voting rights in Zealand Pharma at March 31, 2024March 18, 2024 | msn.comIncrease in opioid use in New Zealand 'should spark concern' - researchersMarch 13, 2024 | markets.businessinsider.comNew Zealand Food Price Inflation Weakest Since 2021April 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.March 1, 2024 | finance.yahoo.comZealand Pharma to Participate in TD Cowen’s 44th Annual Health Care ConferenceMarch 1, 2024 | finance.yahoo.comZealand Pharma to Participate in TD Cowen’s 44th Annual Health Care ConferenceMarch 1, 2024 | seekingalpha.comZealand Pharma A/S (ZEAL) Q4 2023 Earnings Call TranscriptFebruary 27, 2024 | globenewswire.comZealand Pharma convenes its Annual General Meeting 2024February 26, 2024 | msn.comZealand shares surge on liver drug data from Boehringer pactFebruary 26, 2024 | reuters.comZealand Pharma shares surge on liver disease drug trial dataFebruary 19, 2024 | msn.comNew Zealand's birth rate falls to lowest since World War IIFebruary 19, 2024 | msn.comI Walked All Over New Zealand in Amazon's Best-selling, Comfy Merrell Hiking Shoes — and They're on Sale TodayFebruary 18, 2024 | msn.comSouth Korean pharma company SK Biotek to invest up to €35m developing new plantFebruary 6, 2024 | apnews.comSouth Africa 129-7 and trails New Zealand by 382 at lunch on day 3 of the 1st testFebruary 6, 2024 | msn.comNew Zealand calls for Kiwi pilot to be freed a year after Papua kidnappingFebruary 6, 2024 | msn.comNew Zealand expects defence capability report in JuneFebruary 4, 2024 | msn.comCall for time limits on Pharmac's drug assessment processJanuary 31, 2024 | finance.yahoo.comTotal number of shares and voting rights in Zealand Pharma at January 31, 2024January 17, 2024 | finance.yahoo.comZealand Pharma major shareholder announcement: J O Hambro Capital ManagementDecember 29, 2023 | finance.yahoo.comTotal number of shares and voting rights in Zealand Pharma at December 29, 2023December 23, 2023 | finance.yahoo.comU.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facilityDecember 23, 2023 | finance.yahoo.comUPDATE 2-Zealand says US FDA turns down drug for low blood sugar in infantsSee More Headlines Receive ZLDPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:ZLDPF Previous SymbolNASDAQ:ZLDPF CUSIPN/A CIKN/A Webwww.zealandpharma.com Phone45-8877-3600Fax45-8877-3898Employees253Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,130,000.00 Net Margins-203.99% Pretax Margin-191.38% Return on Equity-49.78% Return on Assets-37.76% Debt Debt-to-Equity RatioN/A Current Ratio7.63 Quick Ratio7.59 Sales & Book Value Annual Sales$49.75 million Price / Sales90.32 Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book38.94Miscellaneous Outstanding Shares51,510,000Free FloatN/AMarket Cap$4.49 billion OptionableNot Optionable Beta0.63 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Adam Sinding Steensberg M.D. (Age 50)President & CEO Comp: $1.73MMs. Henriette Wennicke (Age 41)EVP & CFO Comp: $706.47kMr. Ivan Mourits Moller (Age 52)Executive VP & COO Dr. David M. Kendall M.D. (Age 63)Chief Medical Officer and Head of R&D Mr. Mads KronborgHead of Investor Relations & CommunicationMr. Ravinder Singh Chahil (Age 56)EVP & General Counsel Ms. Christina Sonnenborg Bredal (Age 39)Executive VP & Chief People Officer Dr. Jens Damsgaard Mikkelsen M.D.Head of Molecular PharmacologyDr. Danilo VergeHead of Global Medical AffairsLykke RomerVP & Head of Finance and AccountingMore ExecutivesKey CompetitorsHikma PharmaceuticalsOTCMKTS:HKMPFGN Store Nord A/SOTCMKTS:GNNDYOrion OyjOTCMKTS:ORINYAspen PharmacareOTCMKTS:APNHYUDG HealthcareOTCMKTS:UDHCFView All Competitors ZLDPF Stock Analysis - Frequently Asked Questions Should I buy or sell Zealand Pharma A/S stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZLDPF shares. View ZLDPF analyst ratings or view top-rated stocks. How have ZLDPF shares performed in 2024? Zealand Pharma A/S's stock was trading at $55.65 at the start of the year. Since then, ZLDPF stock has increased by 54.8% and is now trading at $86.1650. View the best growth stocks for 2024 here. Are investors shorting Zealand Pharma A/S? Zealand Pharma A/S saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 409,800 shares, an increase of 21.1% from the March 31st total of 338,500 shares. Based on an average daily volume of 4,000 shares, the days-to-cover ratio is presently 102.5 days. View Zealand Pharma A/S's Short Interest. How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (OTCMKTS:ZLDPF) released its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.08. The business earned $3.35 million during the quarter, compared to analysts' expectations of $1.97 million. Zealand Pharma A/S had a negative net margin of 203.99% and a negative trailing twelve-month return on equity of 49.78%. How do I buy shares of Zealand Pharma A/S? Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ZLDPF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
